Relx (LON:REL) had its price objective upped by investment analysts at Deutsche Bank from GBX 1,750 ($22.87) to GBX 1,925 ($25.15) in a report released on Wednesday, June 26th, ThisIsMoney.Co.Uk reports. The brokerage presently has a “hold” rating on the stock. Deutsche Bank’s target price would indicate a potential downside of 0.52% from the company’s previous close.
REL has been the subject of a number of other reports. UBS Group set a $36.00 price target on Halliburton and gave the company a “buy” rating in a research note on Tuesday, April 23rd. Goldman Sachs Group raised Las Vegas Sands to a “buy” rating in a report on Tuesday, June 11th. Berenberg Bank reissued a “hold” rating and issued a $39.00 price objective on shares of Sothebys in a report on Monday, March 4th. Liberum Capital reaffirmed a “sell” rating on shares of Domino’s Pizza Group in a report on Thursday, March 7th. Finally, JPMorgan Chase & Co. set a $195.00 target price on bluebird bio and gave the stock a “buy” rating in a report on Friday, May 17th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of GBX 1,827.33 ($23.88).
Relx stock traded down GBX 34 ($0.44) during midday trading on Wednesday, reaching GBX 1,935 ($25.28). The company’s stock had a trading volume of 2,972,246 shares, compared to its average volume of 4,990,000. The stock’s 50-day simple moving average is GBX 1,911.28. The company has a debt-to-equity ratio of 270.50, a current ratio of 0.44 and a quick ratio of 0.36. Relx has a 52-week low of GBX 1,466.50 ($19.16) and a 52-week high of GBX 1,982.50 ($25.90). The firm has a market capitalization of $37.80 billion and a PE ratio of 27.10.
Relx Company Profile
RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.
Read More: Discount Rate
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.